Severe barbiturate and paracetamol overdose: the simultaneous removal of both poisons by haemoperfusion

MICHAEL Helliwell
M.B., M.R.C.P.

Poisons Unit, Guy's Hospital, London SE1 9RT

Summary
Charcoal haemoperfusion was successful in the treatment of severe butobarbitone poisoning complicated by resistant hypotension. At the same time the rapid removal of paracetamol may have lessened the severity of the subsequent hepatic injury. The mechanism and management of shock associated with barbiturate poisoning, and the possible application of haemoperfusion in paracetamol poisoning are discussed.

Introduction
Charcoal haemoperfusion is an effective method of removing various poisons from the blood (Volans et al., 1977; Hampel and Widdop, 1978) and has advantages compared with haemodialysis (Vale et al., 1975). Most experimental work and the subsequent clinical application of haemoperfusion relate to poisoning with one agent, usually a sedative or hypnotic drug (Widdop et al., 1975; Vale et al., 1975); as yet there have been no reports of the use of this technique in the treatment of mixed drug overdose. A case is now described in which haemoperfusion achieved the simultaneous removal of butobarbitone and paracetamol in a patient severely poisoned by both drugs.

Case report
A 69-year-old woman was admitted to hospital 12 hr after taking an overdose of butobarbitone and paracetamol. Examination revealed her to be hypotensive (systolic blood pressure 60 mmHg) and unresponsive to painful stimuli. She was hypothermic with a rectal temperature of 32°C but respiration and initial blood gas determinations were satisfactory. Plasma concentrations of butobarbitone and paracetamol were 42 mg/l and 150 mg/l respectively, but as the overdose had occurred more than 10 hr before her admission to hospital, specific antidotes to paracetamol were not given. During the next 9 hr her condition deteriorated; she required mechanical ventilation and, despite an infusion of dopamine hydrochloride of 40 μg/kg/min, she remained markedly hypotensive. At this stage the plasma butobarbitone concentration had risen to 70 mg/l whilst the plasma paracetamol concentration remained exceedingly high at 127 mg/l. The patient was therefore transferred to Guy's Hospital for haemoperfusion. On arrival she was breathing spontaneously but remained deeply unconscious (grade IV coma) and hypothermic (core temperature 31°C). Her BP was unrecordable; further arterial blood gas determinations showed a marked metabolic acidosis with a pH of 7-12. Initial management consisted of elevating the central venous pressure to above 5 cm H2O by the infusion of plasma. This was successful in raising the BP and enabled a reduction in the dopamine hydrochloride infusion (Fig. 1).

Haemoperfusion with a 2% acrylic hydrogel-coated charcoal column (Haemocol—100, Smith and Nephew Research Ltd, Harlow, Essex) was commenced and continued for 12 hr, during which time an infusion of colloids maintained the systolic BP above 80 mmHg and allowed further reductions of the dopamine infusion. Heparin was given by infusion to achieve a plasma heparin concentration of 3 u./ml. There were no haemorrhagic complications and at the end of haemoperfusion heparinization was reversed by 100 mg protamine. After 6 hr of haemoperfusion the plasma paracetamol concentration had fallen to 40 mg/l (Fig. 2) and 6 hr later the patient regained oculo-cephalic and oculo-vestibular reflexes. Two hours later she awoke from coma, by which time the plasma butobarbitone concentration had fallen to 38 mg/l. The quantities of butobarbitone and paracetamol removed by haemoperfusion were 3-16 g and 4-75 g respectively. Over the next 7 days, biochemical tests of liver function revealed only moderate hepatic dysfunction with a maximum serum bilirubin and aspartate aminotransferase of 55 μmol/l and 393 i.u./l respectively and a prothrombin time of 40 sec (control 12 sec). Apart from mild, transient jaundice there were no clinical stigmata of liver failure. However, 10 days
Case reports

**Fig. 1.** Effect of volume repletion on systolic blood pressure.

**Fig. 2.** Plasma levels of butobarbitone (---) and paracetamol (---) during haemoperfusion.

following charcoal haemoperfusion, the patient suffered a large gastro-intestinal haemorrhage from a bleeding duodenal ulcer and required emergency surgery. Her postoperative recovery was uneventful and by the time of discharge from hospital her liver function tests had returned to normal apart from a slight elevation of the serum alkaline phosphatase of 142 i.u./l.

**Discussion**

In terms of management, the case described presented dual problems, namely the complications of severe barbiturate poisoning (of which hypotension was the chief concern) and the likelihood of the patient sustaining severe, if not fatal, paracetamol-induced liver damage judging from the initial plasma paracetamol level.

Shock associated with severe barbiturate intoxication is due mainly to an expansion of the capacity of the vascular bed thereby causing a relative hypovolaemic state (Shubin and Weil, 1965) and it is this disparity between vascular capacity and volume that accounts for the reduction in cardiac output and subsequent hypotension. Treatment should therefore be directed towards restoring an effective plasma volume by the infusion of colloids (Shubin and Weil,
1971). It is probable that the large doses of dopamine initially given may have contributed significantly to the patient’s metabolic acidosis since infusion rates of greater than 10 µg/kg/min stimulate α-adrenergic receptors and cause vasoconstriction (Goldberg, 1977) but with the central venous pressure maintained at between 5–10 cm H2O by the infusion of plasma, inotropic support could be gradually withdrawn without any resultant fall in BP.

The other concern was the probability of the patient developing severe hepatic damage as a consequence of the paracetamol overdose. Not only were the plasma paracetamol concentrations exceedingly high in relation to the time after ingestion (Gazzard et al., 1977) but the pre-perfusion plasma paracetamol half-life of 32 hr indicated a poor prognosis (Prescott et al., 1971). Furthermore, the patient had been taking butobarbitone as a hypnotic for many years, thereby making herself particularly vulnerable to the hepatotoxic effect of paracetamol (Wright and Prescott, 1973). Fortunately she emerged with only moderate hepatic damage, as assessed biochemically (Gazzard et al., 1977).

Gazzard et al. (1974) found haemoperfusion to be of little value in the early treatment of paracetamol poisoning, although in this study the use of 10% coated charcoal probably accounted for the small quantities of paracetamol extracted. Specific antidotes however are effective in limiting the degree of hepatic damage (Crome et al., 1976a; Douglas, Hamlyn and James, 1976; Prescott et al., 1977) but are generally accepted as being contra-indicated more than 10 hr following the ingestion of paracetamol (Editorial, 1975; Crome et al., 1976b). Reduction in hepatic perfusion during the stage of hypotension and competition by butobarbitone for microsomal enzymes may have diminished the metabolism of paracetamol to the toxic metabolite; even so this case suggests that haemoperfusion at a late stage may afford some protection to the liver in patients severely poisoned with paracetamol.

Acknowledgment

I wish to thank Dr Roy Goulding and Dr Brian Widdop for their helpful advice and Mr E. Essex who performed the plasma drug analyses.

References


Severe barbiturate and paracetamol overdose: the simultaneous removal of both poisons by haemoperfusion.

M. Helliwell

doi: 10.1136/pgmj.56.655.363

Updated information and services can be found at:
http://pmj.bmj.com/content/56/655/363

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/